


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
ARVN
Arvinas
$13.39
Strengths

Upgraded on attractively valued
ARVN Price Performance
$11.17 (+19.87%)
$9.57 (+39.92%)
$8 (+67.38%)
$18.65 (-28.20%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
Analysts perspectives on the stock desirability, trend direction and growth potential
ARVN has Fair risk level
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
Recent Upgrades and Downgrades
STRONG BUY
Date
Action
Rating
Firm
Jan 07, 2026
Upgrade
Buy
Citigroup
Nov 11, 2025
Reiterate
Overweight
Stephens
Nov 07, 2025
Reiterate
Overweight
Barclays
Oct 30, 2025
Reiterate
Buy
BTIG
PFE
Pfizer
26.78
+3.92%
XNCR
Xencor
11.53
-3.84%
SNY
Sanofi
48.08
+1.24%
NVS
Novartis AG
152.91
+2.04%
MRK
Merck Company
118.33
+2.15%
What is ARVN current stock price?
What are ARVN stock strengths?
What is ARVN Risk Level?
What is ARVN market cap and volume?
What is ARVN current Stock IQ?
Should I buy ARVN stock right now?
Is ARVN a Strong Buy right now?
What does a 'Strong Buy' rating mean for ARVN?
What does a 'Strong Sell' rating mean for ARVN?
What factors influence ARVN's Stock IQ?
Join over 5,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
ARVN
Arvinas
Current Price
$13.39
Runners Also Watch
PFE
Pfizer
26.78
+3.92%
XNCR
Xencor
11.53
-3.84%
SNY
Sanofi
48.08
+1.24%
NVS
Novartis AG
152.91
+2.04%
MRK
Merck Company
118.33
+2.15%

ARVN Price Performance
$11.17 (+19.87%)
$9.57 (+39.92%)
$8 (+67.38%)
$18.65 (-28.20%)
ARVN Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
Analysts perspectives on the stock desirability, trend direction and growth potential
ARVN has Fair risk level
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Jan 07, 2026
Upgrade
Buy
Citigroup
Nov 11, 2025
Reiterate
Overweight
Stephens
Nov 07, 2025
Reiterate
Overweight
Barclays
Oct 30, 2025
Reiterate
Buy
BTIG
ARVN Stock IQ
Stock Insights
Strengths

Upgraded on attractively valued
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ARVN Stock trends
ARVN Stock performance
ARVN Stock analysis
ARVN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.